Murine stromal cells producing hyper-interleukin-6 and Flt3 ligand support expansion of early human hematopoietic progenitor cells without need of exogenous growth factors

Leukemia

Volumn 16, Issue 10, 2002, Pages 2122-2128

  Keller, U ^a   Gotze K S ^a   Duyster, J ^a   Schmidt, B ^a   Rose John, S ^b   Peschel, C ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Flt3 ligand; Hematopoietic; Hyper IL 6; Progenitor cells; Stromal cells

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; FLT3 LIGAND; GROWTH FACTOR; HYBRID PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL STIMULATION; COCULTURE; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENETIC TRANSFECTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; STEM CELL; STROMA CELL; UMBILICAL CORD BLOOD;

EID: 0036798080     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402660     Document Type: Article

References (31)

1. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993; 81: 2844-2853.
2. Lemischka IR. Microenvironmental regulation of hematopoietic stem cells. Stem Cells 1997; 15: 63-68.
3. Moore KA, Ema H, Lemischka IR. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood 1997; 94: 4011-4016.
4. Weiss L, Geduldig U. Barrier cells: stromal regulation of hematopoiesis and blood cell release in normal and stressed murine bone marrow. Blood 1991; 78: 975-990.
5. Dorshkind K. Regulation of hemopoiesis by stromal cells and their products. Annu Rev Immunol 1990; 8: 111-137.
6. + mobilized blood stem cells. Blood 1998; 91: 111-117.
7. low/neg human bone marrow cells. Blood 1999; 94: 529-538.
8. Verfaillie C, Catanzano P. Direct contact with stroma inhibits proliferation of human long-term culture initiating cells. Leukemia 1996; 10: 498-504.
9. Roberts R, Gallagher J, Spooncer E, Allen TD, Bloomfield F, Dexter RM. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 1988; 332: 376-378.
10. Gupta P, Oegema TR, Brazil JJ, Dudek AZ, Slungaard A, Verfaillie CM. Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins. Blood 2000; 95: 147-155.
11. Lyman SD, Jakobsen SEW. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101-1134.
12. Bernat A, Kopf M, Kulbacki R, Weich N, Koehler G, Gutierrez-Ramos JC. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity 1994; 1: 725-731.
13. Luens KM, Travis MA, Chen BP, Hill BL, Scollay R, Murray LJ. Thrombopoietin, kit ligand and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from CD34+Thy1-lin- cells with preserved ability to engraft SCID-hu bone. Blood 1998; 91: 1206-1215.
14. Matsanuga T, Kato T, Miyazaki H, Ogawa M. Thrombopoietin promotes survival of murine hematopoietic long-term reconstituting cells: comparison with the effects of flk2/flt3 ligand and interleukin-6. Blood 1998; 92: 452-461.
15. Kimura T, Sakabe H, Tanimukai S, Abe T, Urata Y, Yasukawa K, Okano A, Taga T, Sugiyama H, Kishimoto T, Sonoda Y. Simultanous activation of signals through gp130, c-kit, and interleukin-3 receptor promotes trilineage blood cell production in the absence of terminally acting lineage-specific factors. Blood 1997; 90: 4767-4778.
16. Ebihara Y, Tsuji K, Lyman SD, Sui Y, Yoshida M, Muraoka K, Tanaka R, Nakahata T. Synergistic action of Flt3 and gp130 signalings in human hematopoiesis. Blood 1997; 90: 4363-4368.
17. Peters M, Müller AM, Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 1998; 92: 3495-3504.
18. Tajima S, Tsuji K, Ebihara Y, Sui X, Tanaka R, Muraoka K, Yoshida M, Yamada K, Yasukawa K, Taga T, Kishimoto T, Nakahata T. Analysis of interleukin-6 receptor and gp130 expression and proliferative capability of human CD34+ cells. J Exp Med 1996; 184: 1357-1364.
19. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J, Rose-John S. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 1997; 15: 142-145.
20. Kollet O, Aviram R, Chebath J, Ben-Hur H, Nagler A, Shultz L, Revel M, Lapidot T. The soluble interleukin-6 (IL-6)receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34+38-/low cells capable of repopulating severe combined immunodeficiency mice. Blood 1999; 94: 923-931.
21. Rappold I, Watt SM, Kusadasi N, Rose-John S, Hatzfeld J, Ploemacher RE. Gp130-signaling synergizes with FL and TPO for the long-term expansion of cord blood progenitors. Leukemia 1999; 13: 2036-2048.
22. Götze KS, Keller U, Rose-John S, Peschel C. gp130-Stimulating designer cytokine H-interleukin-6 synergizes with murine stroma for long-term survival of primitive human hematopoietic progenitor cells. Exp Hematol 2001; 29: 822-832.
23. Itoh K, Tezuka H, Sakoda H, Konno M, Nagata K, Uchiyama T, Uchino H, Mori KJ. Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol 1989; 17: 145-153.
24. Sutherland HJ, Eaves CJ, Landsdorp PM, Thacker JD, Hogge DE. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stroma cells. Blood 1991; 78: 666-672.
25. Fujisaki T, Berger MG, Rose-John S, Eaves CJ. Rapid differentiation of a rare subset of adult human Lin-CD34-CD38- cells stimulated by multiple growth factors in vitro. Blood 1999; 94: 1926-1932.
26. Kusadasi N, van Soest PL, Mayen AE, Koevoet JLM, Ploemacher RE. Successful short-term ex vivo expansion of NOD/SCID repopulating ability and CAFC week 6 from umbilical cord blood. Leukemia 2000; 14: 1944-1953.
27. Shih C-C, Hu MC-T, Hu J, Medeiros J, Forman SJ. Long-term ex vivo maintenance and expansion of transplantable human hematopoietic stem cells. Blood 1999; 94: 1623-1636.
28. Rakemann T, Niehof M, Kubicka S, Fischer M, Manns MP, Rose-John S, Trautwein C. The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcrition in vivo and in vitro. J Biol Chem 1999; 274: 1257-1266.
29. Oh JW, Van Wagoner NJ, Rose-John S, Benveniste EN. Role of soluble IL-6 receptor in inhibition of VCAM-1 gene expression. J Immunol 1998; 161: 4992-4999.
30. Punzel M, Gupta P, Roodell M, Mortari F, Verfaillie CM. Factor(s) secreted by AFT024 fetal liver cells following stimulation with human cytokines are important for human LTC-IC growth. Leukemia 1999; 13: 1079-1784.
31. Toksoz D, KM Zsebo, KA Smith, Hu S, Brankow D, Suggs SV, Martin FH, Williams DA. Support of human hematopoiesis in long-term cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proc Natl Acad Sci USA 1992; 89: 7350-7354.